MedImmune will contribute three clinical and three pre-clinical potential new medicines. This includes inebilizumab, currently in phase 2 trials for ... held on to anifrolumab, a late-stage ...

There is a growing opportunity to expand clinical research capacity in Africa, and numerous organisations are contributing to this effort. To name a few: the African Medicines Agency provides ...

Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn disease.